Similarly, the upregulation of CXCR3 ligands and the increased number of CXCR3+ lymphocytes documented in chronic inflammatory diseases such as rheumatoid arthritis (RA) [14-17], multiple sclerosis (MS) [18,19] and psoriasis [20] indicates the potential importance of CXCR3-mediated leukocyte recruitment in the pathology of these conditions, and suggests the potential utility of the selective CXCR3 antagonist in the treatment and amelioration of these disorders. This evidence concerns the gene CXCR3 and myeloid sarcoma.